M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Cipher starts Phase III study of acne treatment CIP-ISOTRETINOIN
7 October 2009 - Canadian specialty pharmaceutical company Cipher Pharmaceuticals Inc (TSE: DND) said today it has enrolled the first patient in the Phase III safety study of CIP-ISOTRETINOIN, its formulation of isotretinoin, which is used in the treatment of severe, nodular acne.The study is...
If you want to view the full text, you must first purchase archive credits.
Return to Archives
New Search